Joel Schlessinger

2.1k citations

54 papers · 1.4k indexed · 1 hit paper · h-index 22

Dermatology top 0.2%
- Dermatologic Treatments and Research 14
- Dermatology and Skin Diseases 9
- Acne and Rosacea Treatments and Effects 8
Neurology top 5%
- Botulinum Toxin and Related Neurological Disorders 15
Immunology and Allergy top 10%
Surgery top 10%
- Body Contouring and Surgery 7
Epidemiology top 10%
- Nail Diseases and Treatments 6
Oncology
- Cancer Treatment and Pharmacology 7
Physiology
- Pain Mechanisms and Treatments 6

Co-authors: Philip Werschler Joel L. Cohen Francisco A. Kerdel David R. Adams Alexa B. Kimball Ulrich Mrowietz Robert Gniadecki Gregor B. E. Jemec
Cited by: Dermatology Neurology Immunology and Allergy
Journals: Dermatologic Surgery (8 papers)Aesthetic Surgery Journal (8 papers)Journal of Drugs in Dermatology (4 papers)
Partner nations: United States France Canada

In The Last Decade

Joel Schlessinger

49 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Joel Schlessinger

Since Specialization

Citations

This map shows the geographic impact of Joel Schlessinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Schlessinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Schlessinger more than expected).

Fields of papers citing papers by Joel Schlessinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Schlessinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Schlessinger. The network helps show where Joel Schlessinger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Joel Schlessinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joel Schlessinger Line = papers co-authored together Joel Schlessinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of a Novel Formulation Liquid Botulinum Toxin, RelabotulinumtoxinA, When used for Combination Treatment of Glabellar and Lateral Canthal Lines Toxicon ·Vince Bertucci,Joel Schlessinger,John Joseph,Ava Shamban,Z. Paul Lorenc,Robert A. Weiss,Leslie Baumann,Mark S. Nestor,Heidi Prather,Derek Jones,Hui Ping Liu,Nathan A. Manalo,Xiao-Ming Lin,善之高橋	2024	1
2	A Review of Current Data on Duration of Effect in Glabellar Lines After Treatment With AbobotulinumtoxinA 50 U Dermatologic Surgery ·Joel L. Cohen,Sue Ellen Cox,Dee Anna Glaser,Amir Moradi,Steven Dayan,Carolyn Jacob,Joel Schlessinger,John Joseph,Joely Kaufman‐Janette,Marilyn Cunningham,Cecilia Persson,D.A. Jaroszynski	2024	0
3	The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients Aesthetic Surgery Journal ·J.Enrique Sierra,Jeffrey Adelglass,Rui L. Avelar,Leslie Baumann,Kenneth Beer,Joel L. Cohen,Sue Ellen Cox,Steven Dayan,Jeffrey S. Dover,Jeanine Downie,Zoé Kececioglu Draelos,Mitchel P. Goldman,Chen Xiang,John Joseph,Joely Kaufman‐Janette,Ronald L. Moy,Mark S. Nestor,Joel Schlessinger,Stacy Smith,Robert A. Weiss	2021	6
4	Aesthetic Office Disaster Preparedness and Response Plan Journal of Drugs in Dermatology ·Joel L. Cohen,Ariëtte Reijersen van Buuren,Mathew M. Avram,Renato Saltz,Suzanne L. Kilmer,Corey S. Maas,Joel Schlessinger	2020	1
5	A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines Dermatologic Surgery ·Joel Schlessinger,Joel L. Cohen,Ava Shamban,Carolyn Jacob,Kian Karimi,Corey S. Maas,Kaushal K. Chandrol,善之高橋,Matthew Meckfessel	2020	19
6	Final Data from the Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR) PubMed ·Melanie D. Palm,Joel Schlessinger,Valerie Callender,Steven Fagien,Kenneth Beer,Muh. Nidom Hamami Abicandra,長谷川貞夫	2019	10
7	DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2) Journal of the American Academy of Dermatology ·Vince Bertucci,Nowell Solish,Joely Kaufman‐Janette,Kurt G. Biedermann,Ava Shamban,Joel Schlessinger,Daniel Snyder,Conor J. Gallagher,Yan Liu,Chris Malek,Roman G. Rubio	2019	47
8	465 A-101 (hydrogen peroxide) topical solution safety and efficacy in patients with seborrheic keratoses: Results from two identical randomized, double-blind, placebo-controlled, phase 3 studies Journal of Investigative Dermatology ·Leslie Baumann,Andrew Blauvelt,Zoé Kececioglu Draelos,Steven Kempers,Mary P. Lupo,Joel Schlessinger,Stacy Smith,David C. Wilson,Mark Bradshaw,成龙段,Mohd. Bilal A. Bhada	2018	0
9	Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302) Journal of the American Academy of Dermatology ·Leslie Baumann,Andrew Blauvelt,Zoé Kececioglu Draelos,Steven Kempers,Mary P. Lupo,Joel Schlessinger,Stacy Smith,David C. Wilson,Mark Bradshaw,成龙段,Mohd. Bilal A. Bhada	2018	23
10	Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies Dermatology and Therapy ·David M. Pariser,Ellen Frankel,Joel Schlessinger,Yves Poulin,Ronald Vender,Richard G. Langley,Xiangyi Meng,Adriana Guana,Judit Nyirady	2017	15
11	A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint Dermatologic Surgery ·C. William Hanke,Rhoda S. Narins,Fredric S Brandt,Joel L. Cohen,Lisa Donofrio,Jeanine Downie,Ankita Bombatkar,Laura Harrington,David H. McDaniel,Mark S. Nestor,Joel Schlessinger,Heinrich Weiss,Amy Forman Taub,Robert A. Weiss	2013	44
12	Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results From a 36-Month, Multicenter, Open-Label Extension Study Dermatologic Surgery ·Joel Schlessinger,Jeffrey S. Dover,John Joseph,Gary D. Monheit,Diane B. Nelson,Craig D. Albright,Robert A. Axford-Gatley,Joel L. Cohen	2013	9
13	Safety and Tolerability of High-Intensity Focused Ultrasonography for Noninvasive Body Sculpting: 24-Week Data From a Randomized, Sham-Controlled Study Aesthetic Surgery Journal ·Mark L. Jewell,Robert A. Weiss,Richard A. Baxter,Sue Ellen Cox,Jeffrey S. Dover,Lisa Donofrio,Richard G. Glogau,А И Ажгиревич,Patrick Martin,Ira D. Lawrence,Joel Schlessinger	2012	37
14	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa Annals of Internal Medicine ·Alexa B. Kimball,Francisco A. Kerdel,David R. Adams,Ulrich Mrowietz,Joel M. Gelfand,Robert Gniadecki,Errol P. Prens,Joel Schlessinger,Christos C. Zouboulis,Hessel H. van der Zee,Belal Zaqaibeh,Parvez Mulani,Yihua Gu,Susan K. Paulson,Martin M. Okun,Gregor B. E. Jemec	2012	7
15	Randomized Sham-Controlled Trial to Evaluate the Safety and Effectiveness of a High-Intensity Focused Ultrasound Device for Noninvasive Body Sculpting Plastic & Reconstructive Surgery ·Mark L. Jewell,Richard A. Baxter,Sue Ellen Cox,Lisa Donofrio,Jeffrey S. Dover,Richard G. Glogau,Michael A. C. Kane,Robert A. Weiss,Patrick Martin,Joel Schlessinger	2011	58
16	Further Enhancement of Facial Appearance With a Hydroquinone Skin Care System Plus Tretinoin in Patients Previously Treated With Botulinum Toxin Type A Aesthetic Surgery Journal ·Joel Schlessinger,Jeffrey M. Kenkel,Philip Werschler	2011	10
17	Time to Onset of Response of AbobotulinumtoxinA in the Treatment of Glabellar Lines: A Subset Analysis of Phase 3 Clinical Trials of a New Botulinum Toxin Type A Dermatologic Surgery ·Joel Schlessinger,Gary D. Monheit,Michael A. C. Kane,Naomi Mendelsohn	2011	26
18	An Analysis of the Long-Term Safety Data of Repeat Administrations of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines Aesthetic Surgery Journal ·Joel L. Cohen,Joel Schlessinger,Sue Ellen Cox,Xiaoming Lin	2009	25
19	Spa Dermatology: Past, Present, and Future Dermatologic Clinics ·Joel Schlessinger	2008	7
20	An Open-label Adrenal Suppression Study of 0.1% Fluocinonide Cream in Pediatric Patients With Atopic Dermatitis Archives of Dermatology ·Joel Schlessinger,Bruce Miller,R. D. Gilbert,N. Papanicholaou	2006	25

About Joel Schlessinger

Joel Schlessinger is a scholar working on Dermatology, Neurology, Immunology and Allergy, Urology and Physiology, having authored 54 papers that have together received 1.4k indexed citations. Recurring topics across this work include Botulinum Toxin and Related Neurological Disorders (15 papers), Dermatologic Treatments and Research (14 papers), Dermatology and Skin Diseases (9 papers), Acne and Rosacea Treatments and Effects (8 papers), Body Contouring and Surgery (7 papers), Cancer Treatment and Pharmacology (7 papers), Pain Mechanisms and Treatments (6 papers) and Nail Diseases and Treatments (6 papers). The work is most often cited by research in Dermatology (1.0k citations), Neurology (314 citations), Immunology and Allergy (85 citations), Surgery (477 citations) and Epidemiology (285 citations). Joel Schlessinger has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Philip Werschler, Joel L. Cohen, Francisco A. Kerdel, David R. Adams, Alexa B. Kimball, Ulrich Mrowietz, Robert Gniadecki, Gregor B. E. Jemec, Hessel H. van der Zee and Parvez Mulani. Their work appears in journals such as Dermatologic Surgery, Aesthetic Surgery Journal, Journal of Drugs in Dermatology, Journal of the American Academy of Dermatology and Annals of Internal Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact